SI0801564T1 - Use of nebivolol as an anti-atherogenic - Google Patents
Use of nebivolol as an anti-atherogenicInfo
- Publication number
- SI0801564T1 SI0801564T1 SI9530591T SI9530591T SI0801564T1 SI 0801564 T1 SI0801564 T1 SI 0801564T1 SI 9530591 T SI9530591 T SI 9530591T SI 9530591 T SI9530591 T SI 9530591T SI 0801564 T1 SI0801564 T1 SI 0801564T1
- Authority
- SI
- Slovenia
- Prior art keywords
- alpha
- nebivolol
- atherogenic
- chromanmethanol
- iminobis
- Prior art date
Links
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 title 1
- 230000000489 anti-atherogenic effect Effects 0.000 title 1
- 229960000619 nebivolol Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94203775 | 1994-12-28 | ||
PCT/EP1995/005174 WO1996019987A1 (en) | 1994-12-28 | 1995-12-21 | Use of nebivolol as an anti-atherogenic |
EP95942209A EP0801564B1 (en) | 1994-12-28 | 1995-12-21 | Use of nebivolol as an anti-atherogenic |
Publications (1)
Publication Number | Publication Date |
---|---|
SI0801564T1 true SI0801564T1 (en) | 2002-08-31 |
Family
ID=8217503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9530591T SI0801564T1 (en) | 1994-12-28 | 1995-12-21 | Use of nebivolol as an anti-atherogenic |
Country Status (20)
Country | Link |
---|---|
US (2) | US5874461A (pt) |
EP (1) | EP0801564B1 (pt) |
JP (1) | JPH10511655A (pt) |
KR (1) | KR100264348B1 (pt) |
CN (1) | CN1167418C (pt) |
AT (1) | ATE214924T1 (pt) |
AU (1) | AU700364B2 (pt) |
CA (1) | CA2207333C (pt) |
CZ (1) | CZ287513B6 (pt) |
DE (1) | DE69526120T2 (pt) |
DK (1) | DK0801564T3 (pt) |
ES (1) | ES2176354T3 (pt) |
FI (1) | FI118884B (pt) |
HU (1) | HU226208B1 (pt) |
NO (1) | NO315687B1 (pt) |
NZ (1) | NZ298074A (pt) |
PT (1) | PT801564E (pt) |
SI (1) | SI0801564T1 (pt) |
SK (1) | SK282144B6 (pt) |
WO (1) | WO1996019987A1 (pt) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI0801564T1 (en) * | 1994-12-28 | 2002-08-31 | Janssen Pharmaceutica N.V. | Use of nebivolol as an anti-atherogenic |
DE19716120A1 (de) * | 1997-04-17 | 1998-10-22 | Europ Lab Molekularbiolog | Verwendung von cholesterinsenkenden Mitteln |
US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
US6713651B1 (en) | 1999-06-07 | 2004-03-30 | Theravance, Inc. | β2-adrenergic receptor agonists |
JP2000207219A (ja) * | 1999-01-18 | 2000-07-28 | Fujitsu Ten Ltd | 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末 |
US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
US6593497B1 (en) | 1999-06-02 | 2003-07-15 | Theravance, Inc. | β2-adrenergic receptor agonists |
UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
AU2002338528B2 (en) * | 2001-05-02 | 2008-01-24 | Nicox S.A. | Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use |
WO2004042353A2 (en) * | 2002-10-30 | 2004-05-21 | Galileo Pharmaceuticals, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
ITTO20030140U1 (it) * | 2003-09-16 | 2005-03-17 | Interfila Srl | Matita cosmetica |
WO2005032544A1 (en) * | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Treatment of mitochondrial diseases |
US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
CN101006081B (zh) | 2004-07-30 | 2011-02-09 | 托伦特药物有限公司 | 奈必洛尔及其药学可接受盐、制备方法以及奈必洛尔的药物组合物 |
KR20080016527A (ko) * | 2005-01-31 | 2008-02-21 | 밀란 래보러토리즈, 인크. | 하이드록시화된 네비볼롤을 함유하는 약학적 조성물 |
ES2714900T3 (es) | 2005-06-01 | 2019-05-30 | Bioelectron Tech Corp | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
EA019675B1 (ru) | 2006-02-22 | 2014-05-30 | Эдисон Фармасьютикалз, Инк. | Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q |
EA028911B1 (ru) | 2007-11-06 | 2018-01-31 | Биоэлектрон Текнолоджи Корпорейшн | ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ |
US20090181975A1 (en) * | 2008-01-15 | 2009-07-16 | Forest Laboratories Holdings Limited | Nebivolol in the treatment of sexual dysfunction |
US8716527B2 (en) | 2008-03-05 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases |
EP3827815B1 (en) | 2008-09-10 | 2023-09-06 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
SG172275A1 (en) * | 2008-12-19 | 2011-07-28 | Schering Corp | Feed supplement for mammalian cell culture and methods of use |
PT2424495T (pt) | 2009-04-28 | 2018-03-13 | Bioelectron Tech Corp | Tratamento de neuropatia ótica hereditária de leber e atrofia ótica dominante com quinonas de tocotrienol |
US20130065910A1 (en) * | 2010-06-04 | 2013-03-14 | Comprehensive Drug Enterprises Ltd. | Oral meclizine aqueous formulations with taste flavoring agent |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
DE102014107132A1 (de) | 2014-05-20 | 2015-11-26 | Corden Pharma International Gmbh | Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind |
ES2954860T3 (es) * | 2014-10-24 | 2023-11-27 | Launx Biomedical Co Ltd | Uso de azelnidipina en la preparación de una composición medicinal para el tratamiento de cánceres |
WO2016100579A1 (en) | 2014-12-16 | 2016-06-23 | Edison Pharmaceuticals, Inc., | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
JP6905527B2 (ja) | 2015-12-17 | 2021-07-21 | ピーティーシー セラピューティクス, インコーポレイテッド | 酸化ストレス障害を処置するためのフルオロアルキル、フルオロアルコキシ、フェノキシ、ヘテロアリールオキシ、アルコキシ、およびアミノ1,4−ベンゾキノン誘導体 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1337432C (en) * | 1988-03-23 | 1995-10-24 | Raymond M. Xhonneux | Method of lowering the blood pressure |
TW355683B (en) * | 1994-02-17 | 1999-04-11 | Janssen Pharmaceutica Nv | Composition containing micronized nebivolol |
SI0801564T1 (en) * | 1994-12-28 | 2002-08-31 | Janssen Pharmaceutica N.V. | Use of nebivolol as an anti-atherogenic |
-
1995
- 1995-12-21 SI SI9530591T patent/SI0801564T1/xx unknown
- 1995-12-21 WO PCT/EP1995/005174 patent/WO1996019987A1/en active IP Right Grant
- 1995-12-21 CZ CZ19971919A patent/CZ287513B6/cs not_active IP Right Cessation
- 1995-12-21 EP EP95942209A patent/EP0801564B1/en not_active Expired - Lifetime
- 1995-12-21 SK SK856-97A patent/SK282144B6/sk not_active IP Right Cessation
- 1995-12-21 DK DK95942209T patent/DK0801564T3/da active
- 1995-12-21 HU HU9800675A patent/HU226208B1/hu unknown
- 1995-12-21 JP JP8520223A patent/JPH10511655A/ja active Pending
- 1995-12-21 NZ NZ298074A patent/NZ298074A/xx not_active IP Right Cessation
- 1995-12-21 DE DE69526120T patent/DE69526120T2/de not_active Expired - Lifetime
- 1995-12-21 AU AU43477/96A patent/AU700364B2/en not_active Expired
- 1995-12-21 AT AT95942209T patent/ATE214924T1/de active
- 1995-12-21 CA CA002207333A patent/CA2207333C/en not_active Expired - Fee Related
- 1995-12-21 ES ES95942209T patent/ES2176354T3/es not_active Expired - Lifetime
- 1995-12-21 US US08/860,238 patent/US5874461A/en not_active Expired - Lifetime
- 1995-12-21 KR KR1019970703648A patent/KR100264348B1/ko not_active IP Right Cessation
- 1995-12-21 CN CNB951971492A patent/CN1167418C/zh not_active Expired - Lifetime
- 1995-12-21 PT PT95942209T patent/PT801564E/pt unknown
-
1997
- 1997-06-26 NO NO19972980A patent/NO315687B1/no not_active IP Right Cessation
- 1997-06-27 FI FI972793A patent/FI118884B/fi not_active IP Right Cessation
-
1998
- 1998-12-21 US US09/217,728 patent/US6075046A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2176354T3 (es) | 2002-12-01 |
EP0801564B1 (en) | 2002-03-27 |
DE69526120D1 (de) | 2002-05-02 |
NZ298074A (en) | 2001-01-26 |
FI972793A0 (fi) | 1997-06-27 |
CA2207333C (en) | 2006-10-17 |
CA2207333A1 (en) | 1996-07-04 |
ATE214924T1 (de) | 2002-04-15 |
CZ191997A3 (cs) | 1999-01-13 |
CN1167418C (zh) | 2004-09-22 |
SK85697A3 (en) | 2000-04-10 |
MX9704669A (es) | 1997-09-30 |
DE69526120T2 (de) | 2002-11-28 |
HU226208B1 (en) | 2008-06-30 |
US5874461A (en) | 1999-02-23 |
FI118884B (fi) | 2008-04-30 |
AU700364B2 (en) | 1999-01-07 |
CZ287513B6 (en) | 2000-12-13 |
JPH10511655A (ja) | 1998-11-10 |
EP0801564A1 (en) | 1997-10-22 |
DK0801564T3 (da) | 2002-07-15 |
NO315687B1 (no) | 2003-10-13 |
SK282144B6 (sk) | 2001-11-06 |
PT801564E (pt) | 2002-09-30 |
US6075046A (en) | 2000-06-13 |
FI972793A (fi) | 1997-06-27 |
HUT77927A (hu) | 1998-11-30 |
NO972980D0 (no) | 1997-06-26 |
CN1171739A (zh) | 1998-01-28 |
AU4347796A (en) | 1996-07-19 |
WO1996019987A1 (en) | 1996-07-04 |
NO972980L (no) | 1997-06-26 |
KR100264348B1 (ko) | 2000-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI0801564T1 (en) | Use of nebivolol as an anti-atherogenic | |
CA2272584A1 (en) | Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases | |
BG107537A (en) | Method for the inhibition of human tnf alpha activity and its application | |
BG106095A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
HUP9700603A1 (hu) | Gyógyászati készítmény véralvadási zavarok kezelésére | |
EP0923376A4 (en) | TREATMENT OF ASTHMA AND RESPIRATORY DISEASES | |
IL110943A (en) | Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders | |
BG102250A (en) | The use of marigold-extracted glycosides for the treatment of psoriasis | |
DE69725879D1 (de) | VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN | |
ATE231849T1 (de) | Cyclopentabenzofuran-derivate und ihre verwendung | |
BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
BG105275A (en) | Tan-1057 derivatives | |
BG102667A (en) | Diosgenine-containing composition | |
BG102707A (en) | New triazolopurinpurines, method for their preparation and appplication as medicamentous forms | |
IL143382A0 (en) | Human adult astrocytes, their preparation and uses thereof | |
MD970254A (en) | Use of melatonine for treatment of patients having a medicamental dependence | |
AU1278600A (en) | Novel therapeutic application of nicergoline | |
TW330933B (en) | Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes | |
AU2392797A (en) | Use of benzonaphthalene derivatives for the manufacture of medicaments for the treatment of diseases of the nervous system | |
WO1996025931A3 (en) | Use of fused benzothiazoles as neuroprotectants | |
AU1569700A (en) | Novel therapeutic application of low molecular weight heparin | |
HUP0004647A2 (hu) | Glükóz-amino-glükánok alkalmazása diabétesszel társult szembetegségek kezelésére szolgáló gyógyszerkészítmények előállítására | |
AU1278700A (en) | Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline | |
MX9706931A (es) | Derivados de amida de acido-2-ciano-3,5-dihidroxi-hex-2-eno-carboxilico. | |
BG102864A (en) | Application of phosphonic acid esters for the treatment of functional disorders of the brain and depressions |